Status:
RECRUITING
Attribution of Toxicities Due to Radiotherapy and Immuno-Biological Therapies
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Conditions:
Cancer
Radiotherapy Side Effect
Eligibility:
All Genders
18+ years
Brief Summary
Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy...
Detailed Description
Every year, new molecular agents enter the market with more and more patients receiving these treatments, especially in the metastatic setting. These molecular agents could correspond to immunotherapy...
Eligibility Criteria
Inclusion
- Consent to be part of the AtTRIBut registry
- Prior histological diagnosis of primary cancer.
- If the patient has metastatic disease, there must be radiological or pathological evidence of metastasis
- Age\> 18 years
- Receiving a molecular therapy
- Indicated to receive radiotherapy
- Radiation therapy can be administered using 3D conventional, IMRT or SBRT techniques.
Exclusion
- • Refusal or inability to receive radiotherapy
Key Trial Info
Start Date :
September 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
3600 Patients enrolled
Trial Details
Trial ID
NCT04115267
Start Date
September 13 2019
End Date
September 30 2025
Last Update
June 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada, H2X 0A9